{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:27:01Z","timestamp":1789244821439,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007432","name":"Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences","doi-asserted-by":"publisher","award":["ICR-100-500"],"award-info":[{"award-number":["ICR-100-500"]}],"id":[{"id":"10.13039\/501100007432","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"publisher","award":["22827"],"award-info":[{"award-number":["22827"]}],"id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Head and Neck Pathol"],"DOI":"10.1007\/s12105-022-01486-x","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T10:04:07Z","timestamp":1664359447000},"page":"178-192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Simultaneous Expression of PD-1 and PD-L1 in Peripheral and Central Immune Cells and Tumor Cells in the Benign and Malignant Salivary Gland Tumors Microenvironment"],"prefix":"10.1007","volume":"17","author":[{"given":"Sajjad","family":"Gerdabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Asadian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razie","family":"Kiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijan","family":"Khademi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Haghshenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4158-9128","authenticated-orcid":false,"given":"Nasrollah","family":"Erfani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"1486_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19010179","author":"M \u017burek","year":"2021","unstructured":"\u017burek M, Rzepakowska A, Jasak K, Niemczyk K. The epidemiology of salivary glands pathologies in adult population over 10 years in poland-cohort study. Int J Environ Res Public Health. 2021. https:\/\/doi.org\/10.3390\/ijerph19010179.","journal-title":"Int J Environ Res Public Health"},{"key":"1486_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.coms.2018.08.007","volume":"31","author":"ER Carlson","year":"2019","unstructured":"Carlson ER, Schlieve T. Salivary gland malignancies. Oral Maxillofac Surg Clin North Am. 2019;31:125\u201344. https:\/\/doi.org\/10.1016\/j.coms.2018.08.007.","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"1486_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000442119","volume":"78","author":"PJ Bradley","year":"2016","unstructured":"Bradley PJ. Classification of salivary gland neoplasms. Adv Otorhinolaryngol. 2016;78:1\u20138. https:\/\/doi.org\/10.1159\/000442119.","journal-title":"Adv Otorhinolaryngol"},{"key":"1486_CR4","doi-asserted-by":"publisher","first-page":"2897827","DOI":"10.1155\/2018\/2897827","volume":"2018","author":"P Sowa","year":"2018","unstructured":"Sowa P, Goroszkiewicz K, Szydelko J, Chechlinska J, Pluta K, Domka W, et al. A review of selected factors of salivary gland tumour formation and malignant transformation. Biomed Res Int. 2018;2018:2897827. https:\/\/doi.org\/10.1155\/2018\/2897827.","journal-title":"Biomed Res Int"},{"key":"1486_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/hed.25499","volume":"41","author":"AV Mantravadi","year":"2019","unstructured":"Mantravadi AV, Moore MG, Rassekh CH. AHNS series: do you know your guidelines? Diagnosis and management of salivary gland tumors. Head Neck. 2019;41:269\u201380. https:\/\/doi.org\/10.1002\/hed.25499.","journal-title":"Head Neck"},{"key":"1486_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41368-019-0059-9","volume":"11","author":"G Yu","year":"2019","unstructured":"Yu G, Peng X. Conservative and functional surgery in the treatment of salivary gland tumours. Int J Oral Sci. 2019;11:22. https:\/\/doi.org\/10.1038\/s41368-019-0059-9.","journal-title":"Int J Oral Sci"},{"key":"1486_CR7","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1001\/jamaoto.2016.2168","volume":"142","author":"A Amini","year":"2016","unstructured":"Amini A, Waxweiler TV, Brower JV, Jones BL, McDermott JD, Raben D, et al. Association of adjuvant chemoradiotherapy vs radiotherapy alone with survival in patients with resected major salivary gland carcinoma: data from the national cancer data base. JAMA Otolaryngol Head Neck Surg. 2016;142:1100\u201310. https:\/\/doi.org\/10.1001\/jamaoto.2016.2168.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"1486_CR8","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20:651\u201368. https:\/\/doi.org\/10.1038\/s41577-020-0306-5.","journal-title":"Nat Rev Immunol"},{"key":"1486_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030738","author":"RK Vaddepally","year":"2020","unstructured":"Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12030738.","journal-title":"Cancers (Basel)"},{"key":"1486_CR10","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1093\/annonc\/mdx399","volume":"28","author":"JS Ross","year":"2017","unstructured":"Ross JS, Gay LM, Wang K, Vergilio JA, Suh J, Ramkissoon S, et al. Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies. Ann Oncol. 2017;28:2539\u201346. https:\/\/doi.org\/10.1093\/annonc\/mdx399.","journal-title":"Ann Oncol"},{"key":"1486_CR11","doi-asserted-by":"publisher","first-page":"25631","DOI":"10.18632\/oncotarget.4554","volume":"6","author":"S Kato","year":"2015","unstructured":"Kato S, Elkin SK, Schwaederle M, Tomson BN, Helsten T, Carter JL, et al. Genomic landscape of salivary gland tumors. Oncotarget. 2015;6:25631\u201345. https:\/\/doi.org\/10.18632\/oncotarget.4554.","journal-title":"Oncotarget"},{"key":"1486_CR12","doi-asserted-by":"publisher","first-page":"12724","DOI":"10.1038\/s41598-019-49215-9","volume":"9","author":"D Vital","year":"2019","unstructured":"Vital D, Ikenberg K, Moch H, R\u00f6ssle M, Huber GF. The expression of PD-L1 in salivary gland carcinomas. Sci Rep. 2019;9:12724. https:\/\/doi.org\/10.1038\/s41598-019-49215-9.","journal-title":"Sci Rep"},{"key":"1486_CR13","doi-asserted-by":"publisher","first-page":"E1481","DOI":"10.1002\/lary.29120","volume":"131","author":"F Sato","year":"2021","unstructured":"Sato F, Ono T, Kawahara A, Matsuo K, Kondo R, Sato K, et al. Prognostic value of tumor proportion score in salivary gland carcinoma. Laryngoscope. 2021;131:E1481\u20138. https:\/\/doi.org\/10.1002\/lary.29120.","journal-title":"Laryngoscope"},{"key":"1486_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9020097","author":"M Kuchar","year":"2021","unstructured":"Kuchar M, Strizova Z, Capkova L, Komarc M, Skrivan J, Bartunkova J, et al. The periphery of salivary gland carcinoma tumors reveals a PD-L1\/PD-1 biomarker niche for the evaluation of disease severity and tumor-immune system interplay. Biomedicines. 2021. https:\/\/doi.org\/10.3390\/biomedicines9020097.","journal-title":"Biomedicines"},{"key":"1486_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113107","author":"C Porcheri","year":"2020","unstructured":"Porcheri C, Meisel CT, Mitsiadis TA. Molecular and cellular modelling of salivary gland tumors open new landscapes in diagnosis and treatment. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12113107.","journal-title":"Cancers (Basel)"},{"key":"1486_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040873","author":"HM Witte","year":"2020","unstructured":"Witte HM, Gebauer N, Lapp\u00f6hn D, Umathum VG, Riecke A, Arndt A, et al. Prognostic impact of PD-L1 expression in malignant salivary gland tumors as assessed by established scoring criteria: tumor proportion score (TPS), combined positivity score (CPS), and immune cell (IC) infiltrate. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12040873.","journal-title":"Cancers (Basel)"},{"key":"1486_CR17","doi-asserted-by":"publisher","first-page":"701181","DOI":"10.3389\/fonc.2021.701181","volume":"11","author":"Q Fang","year":"2021","unstructured":"Fang Q, Wu Y, Du W, Zhang X, Chen D. Incidence and prognostic significance of PD-L1 expression in high-grade salivary gland carcinoma. Front Oncol. 2021;11:701181. https:\/\/doi.org\/10.3389\/fonc.2021.701181.","journal-title":"Front Oncol"},{"key":"1486_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1556\/1646.8.2016.2.2","volume":"8","author":"YV Kuzenko","year":"2016","unstructured":"Kuzenko YV, Romanuk AM, Dyachenko OO, Hudymenko O. Pathogenesis of warthin\u2019s tumors. Interv Med Appl Sci. 2016;8:41\u20138. https:\/\/doi.org\/10.1556\/1646.8.2016.2.2.","journal-title":"Interv Med Appl Sci"},{"key":"1486_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.imlet.2015.02.008","volume":"164","author":"MR Haghshenas","year":"2015","unstructured":"Haghshenas MR, Khademi B, Faghih Z, Ghaderi A, Erfani N. Immune regulatory cells and IL17-producing lymphocytes in patients with benign and malignant salivary gland tumors. Immunol Lett. 2015;164:109\u201316. https:\/\/doi.org\/10.1016\/j.imlet.2015.02.008.","journal-title":"Immunol Lett"},{"key":"1486_CR20","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/odi.12496","volume":"22","author":"MR Haghshenas","year":"2016","unstructured":"Haghshenas MR, Khademi B, Ashraf MJ, Ghaderi A, Erfani N. Helper and cytotoxic T-cell subsets (Th1, Th2, Tc1, and Tc2) in benign and malignant salivary gland tumors. Oral Dis. 2016;22:566\u201372. https:\/\/doi.org\/10.1111\/odi.12496.","journal-title":"Oral Dis"},{"key":"1486_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/08830185.2021.1958806","author":"MR Haghshenas","year":"2021","unstructured":"Haghshenas MR, Ghaderi H, Daneste H, Ghaderi A. Immunological and biological dissection of normal and tumoral salivary glands. Int Rev Immunol. 2021. https:\/\/doi.org\/10.1080\/08830185.2021.1958806.","journal-title":"Int Rev Immunol"},{"key":"1486_CR22","doi-asserted-by":"publisher","first-page":"6640","DOI":"10.1073\/pnas.1921445117","volume":"117","author":"X Wang","year":"2020","unstructured":"Wang X, Yang X, Zhang C, Wang Y, Cheng T, Duan L, et al. Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy. Proc Natl Acad Sci USA. 2020;117:6640\u201350. https:\/\/doi.org\/10.1073\/pnas.1921445117.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1486_CR23","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/hep.29360","volume":"66","author":"H Li","year":"2017","unstructured":"Li H, Li X, Liu S, Guo L, Zhang B, Zhang J, et al. Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1. Hepatology. 2017;66:1920\u201333. https:\/\/doi.org\/10.1002\/hep.29360.","journal-title":"Hepatology"},{"key":"1486_CR24","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","volume":"162","author":"S Kleffel","year":"2015","unstructured":"Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell. 2015;162:1242\u201356. https:\/\/doi.org\/10.1016\/j.cell.2015.08.052.","journal-title":"Cell"},{"key":"1486_CR25","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1111\/febs.14937","volume":"286","author":"M Sakai","year":"2019","unstructured":"Sakai M, Fukumoto M, Ikai K, Ono Minagi H, Inagaki S, Kogo M, et al. Role of the mTOR signalling pathway in salivary gland development. Febs j. 2019;286:3701\u201317. https:\/\/doi.org\/10.1111\/febs.14937.","journal-title":"Febs j"},{"key":"1486_CR26","doi-asserted-by":"publisher","first-page":"9143","DOI":"10.1158\/0008-5472.Can-10-1758","volume":"70","author":"CR Diegel","year":"2010","unstructured":"Diegel CR, Cho KR, El-Naggar AK, Williams BO, Lindvall C. Mammalian target of rapamycin-dependent acinar cell neoplasia after inactivation of Apc and Pten in the mouse salivary gland: implications for human acinic cell carcinoma. Cancer Res. 2010;70:9143\u201352. https:\/\/doi.org\/10.1158\/0008-5472.Can-10-1758.","journal-title":"Cancer Res"},{"key":"1486_CR27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1159\/000512060","volume":"14","author":"T Sato","year":"2021","unstructured":"Sato T, Maeta T, Abe R, Yamada H, Ishida K, Yashima-Abo A, et al. Successful treatment with nivolumab in a patient with metastatic salivary duct carcinoma. Case Rep Oncol. 2021;14:343\u20136. https:\/\/doi.org\/10.1159\/000512060.","journal-title":"Case Rep Oncol"},{"key":"1486_CR28","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.2147\/ott.S134589","volume":"10","author":"H Chang","year":"2017","unstructured":"Chang H, Kim JS, Choi YJ, Cho JG, Woo JS, Kim A, et al. Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors. Onco Targets Ther. 2017;10:2983\u201392. https:\/\/doi.org\/10.2147\/ott.S134589.","journal-title":"Onco Targets Ther"},{"key":"1486_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.oraloncology.2018.11.028","volume":"88","author":"C Mosconi","year":"2019","unstructured":"Mosconi C, de Arruda JAA, de Farias ACR, Oliveira GAQ, de Paula HM, Fonseca FP, et al. Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands. Oral Oncol. 2019;88:95\u2013101. https:\/\/doi.org\/10.1016\/j.oraloncology.2018.11.028.","journal-title":"Oral Oncol"},{"key":"1486_CR30","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.canlet.2019.10.013","volume":"468","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Zhan H. Communication between EMT and PD-L1 signaling: new insights into tumor immune evasion. Cancer Lett. 2020;468:72\u201381. https:\/\/doi.org\/10.1016\/j.canlet.2019.10.013.","journal-title":"Cancer Lett"},{"key":"1486_CR31","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.18632\/oncotarget.1606","volume":"5","author":"YL Tang","year":"2014","unstructured":"Tang YL, Fan YL, Jiang J, Li KD, Zheng M, Chen W, et al. C-kit induces epithelial-mesenchymal transition and contributes to salivary adenoid cystic cancer progression. Oncotarget. 2014;5:1491\u2013501. https:\/\/doi.org\/10.18632\/oncotarget.1606.","journal-title":"Oncotarget"},{"key":"1486_CR32","first-page":"969","volume":"54","author":"AS Enescu","year":"2013","unstructured":"Enescu AS, M\u0103rg\u0103ritescu CL, Cr\u0103i\u0163oiu MM, Enescu A, Cr\u0103i\u0163oiu \u015e. The involvement of growth differentiation factor 5 (GDF5) and aggrecan in the epithelial-mesenchymal transition of salivary gland pleomorphic adenoma. Rom J Morphol Embryol. 2013;54:969\u201376.","journal-title":"Rom J Morphol Embryol"},{"key":"1486_CR33","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1007\/s12325-019-01007-3","volume":"36","author":"H Hellquist","year":"2019","unstructured":"Hellquist H, Paiva-Correia A, Vander Poorten V, Quer M, Hernandez-Prera JC, Andreasen S, et al. Analysis of the clinical relevance of histological classification of benign epithelial salivary gland tumours. Adv Ther. 2019;36:1950\u201374. https:\/\/doi.org\/10.1007\/s12325-019-01007-3.","journal-title":"Adv Ther"},{"key":"1486_CR34","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1288\/00005537-199509000-00011","volume":"105","author":"KW Chin","year":"1995","unstructured":"Chin KW, Billings KR, Ishiyama A, Wang MB, Wackym PA. Characterization of lymphocyte subpopulations in warthin\u2019s tumor. Laryngoscope. 1995;105:928\u201333. https:\/\/doi.org\/10.1288\/00005537-199509000-00011.","journal-title":"Laryngoscope"},{"key":"1486_CR35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1600-0714.2008.00676.x","volume":"38","author":"ID O'Neill","year":"2009","unstructured":"O\u2019Neill ID. New insights into the nature of warthin\u2019s tumour. J Oral Pathol Med. 2009;38:145\u20139. https:\/\/doi.org\/10.1111\/j.1600-0714.2008.00676.x.","journal-title":"J Oral Pathol Med"},{"key":"1486_CR36","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s12105-014-0581-1","volume":"9","author":"A Triantafyllou","year":"2015","unstructured":"Triantafyllou A, Thompson LD, Devaney KO, Bell D, Hunt JL, Rinaldo A, et al. Functional histology of salivary gland pleomorphic adenoma: an appraisal. Head Neck Pathol. 2015;9:387\u2013404. https:\/\/doi.org\/10.1007\/s12105-014-0581-1.","journal-title":"Head Neck Pathol"},{"key":"1486_CR37","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.36740\/WLek202011103","volume":"73","author":"IS Brodetskyi","year":"2020","unstructured":"Brodetskyi IS, Dyadyk OO, Myroshnychenko MS, Zaritska VI. Morphological characteristics of pleomorphic adenomas of salivary glands (analysis of the surgical material). Wiad Lek. 2020;73:2339\u201344.","journal-title":"Wiad Lek"},{"key":"1486_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13050965","author":"S Hiss","year":"2021","unstructured":"Hiss S, Eckstein M, Segschneider P, Mantsopoulos K, Iro H, Hartmann A, et al. Tumour-infiltrating lymphocytes (TILs) and PD-L1 expression correlate with lymph node metastasis, high-grade transformation and shorter metastasis-free survival in patients with acinic cell carcinoma (AciCC) of the salivary glands. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13050965.","journal-title":"Cancers (Basel)"},{"key":"1486_CR39","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12885-018-4069-3","volume":"18","author":"K Harada","year":"2018","unstructured":"Harada K, Ferdous T, Ueyama Y. PD-L1 expression in malignant salivary gland tumors. BMC Cancer. 2018;18:156. https:\/\/doi.org\/10.1186\/s12885-018-4069-3.","journal-title":"BMC Cancer"},{"key":"1486_CR40","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.urolonc.2019.03.014","volume":"37","author":"Z Strizova","year":"2019","unstructured":"Strizova Z, Taborska P, Stakheev D, Partlov\u00e1 S, Havlova K, Vesely S, et al. NK and T cells with a cytotoxic\/migratory phenotype accumulate in peritumoral tissue of patients with clear cell renal carcinoma. Urol Oncol. 2019;37:503\u20139. https:\/\/doi.org\/10.1016\/j.urolonc.2019.03.014.","journal-title":"Urol Oncol"},{"key":"1486_CR41","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1007\/s00432-020-03258-y","volume":"146","author":"Z Strizova","year":"2020","unstructured":"Strizova Z, Snajdauf M, Stakheev D, Taborska P, Vachtenheim J Jr, Biskup J, et al. The paratumoral immune cell signature reveals the potential for the implementation of immunotherapy in esophageal carcinoma patients. J Cancer Res Clin Oncol. 2020;146:1979\u201392. https:\/\/doi.org\/10.1007\/s00432-020-03258-y.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1486_CR42","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1158\/1078-0432.Ccr-19-2214","volume":"26","author":"CP Rodriguez","year":"2020","unstructured":"Rodriguez CP, Wu QV, Voutsinas J, Fromm JR, Jiang X, Pillarisetty VG, et al. A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer. Clin Cancer Res. 2020;26:837\u201345. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-2214.","journal-title":"Clin Cancer Res"},{"key":"1486_CR43","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1097\/coc.0000000000000429","volume":"41","author":"RB Cohen","year":"2018","unstructured":"Cohen RB, Delord JP, Doi T, Piha-Paul SA, Liu SV, Gilbert J, et al. Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study. Am J Clin Oncol. 2018;41:1083\u20138. https:\/\/doi.org\/10.1097\/coc.0000000000000429.","journal-title":"Am J Clin Oncol"},{"key":"1486_CR44","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s12032-015-0501-6","volume":"32","author":"J Zhang","year":"2015","unstructured":"Zhang J, Fang W, Qin T, Yang Y, Hong S, Liang W, et al. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma. Med Oncol. 2015;32:86. https:\/\/doi.org\/10.1007\/s12032-015-0501-6.","journal-title":"Med Oncol"},{"key":"1486_CR45","doi-asserted-by":"publisher","first-page":"4884","DOI":"10.7150\/jca.44506","volume":"11","author":"H Yin","year":"2020","unstructured":"Yin H, Tang Y, Guo Y, Wen S. Immune microenvironment of thyroid cancer. J Cancer. 2020;11:4884\u201396. https:\/\/doi.org\/10.7150\/jca.44506.","journal-title":"J Cancer"},{"key":"1486_CR46","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ijrobp.2020.08.018","volume":"109","author":"U Mahmood","year":"2021","unstructured":"Mahmood U, Bang A, Chen YH, Mak RH, Lorch JH, Hanna GJ, et al. A randomized phase 2 study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma. Int J Radiat Oncol Biol Phys. 2021;109:134\u201344. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.08.018.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1486_CR47","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1158\/1078-0432.Ccr-14-2926","volume":"21","author":"NA Giraldo","year":"2015","unstructured":"Giraldo NA, Becht E, Pag\u00e8s F, Skliris G, Verkarre V, Vano Y, et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin Cancer Res. 2015;21:3031\u201340. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-14-2926.","journal-title":"Clin Cancer Res"},{"key":"1486_CR48","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","volume":"14","author":"WH Fridman","year":"2017","unstructured":"Fridman WH, Zitvogel L, Saut\u00e8s-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14:717\u201334. https:\/\/doi.org\/10.1038\/nrclinonc.2017.101.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Head and Neck Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12105-022-01486-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12105-022-01486-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12105-022-01486-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T06:32:39Z","timestamp":1680244359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12105-022-01486-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["1486"],"URL":"https:\/\/doi.org\/10.1007\/s12105-022-01486-x","relation":{},"ISSN":["1936-0568"],"issn-type":[{"value":"1936-0568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]},"assertion":[{"value":"3 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"<b>T<\/b>here was no conflict of interest among the authors References.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved by the Ethics Committee of Shiraz University of Medical Sciences (IR.SUMS.REC.1400.371).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided informed written consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The Authors informed consent to publication of the Work in any publications.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}